TABLE 1.
Baseline patient characteristics split between multiple sclerosis subtype
| Characteristic | RRMS | SPMS | PPMS |
|---|---|---|---|
| Participants, n (row %) | 54 (57.4) | 29 (30.9) | 11 (11.7) |
| Age, years, mean (SD) | 42.0 (9.8) | 53.3 (6.5) | 52.5 (9.4) |
| Sex, n (%) | |||
| Female | 44 (81.5) | 16 (55.2) | 8 (72.7) |
| Male | 10 (18.5) | 13 (44.8) | 3 (27.3) |
| Level of education, n (%) | |||
| Low | 2 (3.7) | 0 (0.0) | 1 (9.1) |
| Middle | 15 (27.8) | 13 (44.8) | 3 (27.3) |
| High | 37 (68.5) | 16 (55.2) | 7 (63.6) |
| Disease duration, years, median (IQR) | |||
| Since diagnosis | 4.5 (2.6–10.4) | 12.1 (7.3–23.3) | 2.9 (0.8–4.7) |
| Since onset | 8.3 (4.4–14.8) | 13.9 (9.6–27.9) | 6.1 (4.0–11.8) |
| EDSS, median (IQR) | 3.0 (2.5–4.0) | 4.0 (3.5–6.0) | 4.0 (3.0–5.5) |
| DMT use, n (%) | 43 (79.6) a | 12 (41.4) b | 2 (18.2) c |
Abbreviations: DMT, disease‐modifying therapy; EDSS, Expanded Disability Status Scale; IQR, interquartile range; PPMS, primary progressive multiple sclerosis; RRMS, relapsing‐remitting multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.
a
Dimethyl fumarate, n = 10; interferon beta, n = 8; glatiramer acetate, n = 7; teriflunomide, n = 6; ocrelizumab, n = 5; fingolimod, n = 4; natalizumab, n = 2; alemtuzumab, n = 1.
b
Dimethyl fumarate, n = 4; glatiramer acetate, n = 3; interferon beta, teriflunomide, natalizumab, fingolimod, and ocrelizumab, each n = 1.
c
Ocrelizumab, n = 2.